TYMS and non-small cell lung carcinoma: Takezawa et al. (2011) found that the expression of TYMS could be adopted as a potential predictor of the response of NSCLC patients to pemetrexed chemotherapy, because the high expression of TYMS would reduce sensitivity to pemetrexed.